THOUSAND OAKS, Calif.,
June 17, 2016 /PRNewswire/
-- Amgen (NASDAQ:AMGN) today announced the appointment of
Esteban Santos as executive vice
president, Operations, effective July 25,
2016, reporting to Robert A.
Bradway, chairman and chief executive officer. Santos will
be responsible for Amgen's Operations organization which
encompasses manufacturing, process development, quality,
engineering and global supply chain. He will succeed Madhavan (Madhu) Balachandran, 65, who is
retiring at the end of the year.
Santos, 48, has been senior vice president, Manufacturing with
responsibilities for worldwide product supply since 2013. He joined
Amgen in 2007 and previously held various leadership roles,
including vice president, Drug Product; vice president, Site
Operations; vice president, Manufacturing; and vice president,
Engineering.
Before joining Amgen, Santos was site general manager for the
Johnson & Johnson (J&J) Cordis operation in Puerto Rico. Prior to J&J, Santos held
several management positions in General Electric's industrial and
transportation businesses in Puerto
Rico, Connecticut, and
Pennsylvania. Santos holds a
bachelor of science degree in electrical engineering from the
University of Puerto Rico – Mayagüez
and a master of science in management from the Rensselaer Polytechnic Institute, Hartford, Connecticut.
Bradway said, "Esteban is a talented leader with a proven track
record. I'm confident that Esteban and our Operations team will
maintain our track record of industry-leading performance in
serving 'every patient, every time' as we expand globally, launch
new products and introduce our next-generation of biomanufacturing
technologies."
Succeeding Santos as senior vice president, Manufacturing will
be Robert Maroney, who is currently
vice president, Site Operations at Amgen Manufacturing, Ltd. in
Juncos, Puerto Rico.
About Amgen
Amgen is committed to unlocking the
potential of biology for patients suffering from serious illnesses
by discovering, developing, manufacturing and delivering innovative
human therapeutics. This approach begins by using tools like
advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages
its expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer
since 1980, Amgen has grown to be one of the world's leading
independent biotechnology companies, has reached millions of
patients around the world and is developing a pipeline of medicines
with breakaway potential.
For more information, visit www.amgen.com and follow us on
www.twitter.com/amgen.
Forward-Looking Statements
This news release contains
forward-looking statements that are based on the current
expectations and beliefs of Amgen. All statements, other than
statements of historical fact, are statements that could be deemed
forward-looking statements, including statements regarding the
timing and completion of the Exchange Offers, estimates of
revenues, operating margins, capital expenditures, cash, other
financial metrics, expected legal, arbitration, political,
regulatory or clinical results or practices, customer and
prescriber patterns or practices, reimbursement activities and
outcomes and other such estimates and results. Forward-looking
statements involve significant risks and uncertainties, including
those discussed below and more fully described in
the SEC reports filed by Amgen, including our most
recent annual report on Form 10-K and any subsequent periodic
reports on Form 10-Q and Form 8-K. Unless otherwise
noted, Amgen is providing this information as of the date
of this news release and does not undertake any obligation to
update any forward-looking statements contained in this document as
a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual
results may differ materially from those we project. Our results
may be affected by our ability to successfully market both new and
existing products domestically and internationally, clinical and
regulatory developments involving current and future products,
sales growth of recently launched products, competition from other
products including biosimilars, difficulties or delays in
manufacturing our products and global economic conditions. In
addition, sales of our products are affected by pricing pressure,
political and public scrutiny and reimbursement policies imposed by
third-party payers, including governments, private insurance plans
and managed care providers and may be affected by regulatory,
clinical and guideline developments and domestic and international
trends toward managed care and healthcare cost containment.
Furthermore, our research, testing, pricing, marketing and other
operations are subject to extensive regulation by domestic and
foreign government regulatory authorities. We or others could
identify safety, side effects or manufacturing problems with our
products after they are on the market. Our business may be impacted
by government investigations, litigation and product liability
claims. In addition, our business may be impacted by the adoption
of new tax legislation or exposure to additional tax liabilities.
If we fail to meet the compliance obligations in the corporate
integrity agreement between us and the U.S. government, we could
become subject to significant sanctions. Further, while we
routinely obtain patents for our products and technology, the
protection offered by our patents and patent applications may be
challenged, invalidated or circumvented by our competitors, or we
may fail to prevail in present and future intellectual property
litigation. We perform a substantial amount of our commercial
manufacturing activities at a few key facilities and also depend on
third parties for a portion of our manufacturing activities, and
limits on supply may constrain sales of certain of our current
products and product candidate development. In addition, we compete
with other companies with respect to many of our marketed products
as well as for the discovery and development of new products.
Discovery or identification of new product candidates cannot be
guaranteed and movement from concept to product is uncertain;
consequently, there can be no guarantee that any particular product
candidate will be successful and become a commercial product.
Further, some raw materials, medical devices and component parts
for our products are supplied by sole third-party suppliers. The
discovery of significant problems with a product similar to one of
our products that implicate an entire class of products could have
a material adverse effect on sales of the affected products and on
our business and results of operations. Our efforts to acquire
other companies or products and to integrate the operations of
companies we have acquired may not be successful. We may not be
able to access the capital and credit markets on terms that are
favorable to us, or at all. We are increasingly dependent on
information technology systems, infrastructure and data security.
Our stock price is volatile and may be affected by a number of
events. Our business performance could affect or limit the ability
of our Board of Directors to declare a dividend or our ability to
pay a dividend or repurchase our common stock.
CONTACT: Amgen, Thousand
Oaks
Kristen Davis, 805-447-3008
(media)
Arvind Sood, 805-447-1060
(investors)
Logo - http://photos.prnewswire.com/prnh/20081015/AMGENLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amgen-appoints-esteban-santos-executive-vice-president-operations-300286635.html
SOURCE Amgen